179 related articles for article (PubMed ID: 25667625)
1. Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia.
Wu FP; Wang J; Wang H; Li N; Guo Y; Cheng YJ; Liu Q; Yang XR
Exp Ther Med; 2015 Mar; 9(3):761-765. PubMed ID: 25667625
[TBL] [Abstract][Full Text] [Related]
2. [Clinical observation of the salvage therapy using pegylated recombinant human granulocyte colony stimulating factor for grade IV neutropenia induced by concurrent chemoradiotherapy].
Wu F; Wang H; Li N; Guo Y; Cheng Y; Liu Q; Yang X; Wan X; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):708-12. PubMed ID: 25564064
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
Ji X; Xu L; Pan P; Xu Z; Wang A; Li Y
Thorac Cancer; 2022 Jan; 13(1):117-125. PubMed ID: 34791805
[TBL] [Abstract][Full Text] [Related]
7. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
[TBL] [Abstract][Full Text] [Related]
8. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
Zou D; Guo M; Zhou Q
BMC Cancer; 2021 Jun; 21(1):661. PubMed ID: 34078317
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
Jiang Y; Zhang J; Zhong J; Liao H; Zhang J; Liu Y; Liang Y; Li H
BMC Cancer; 2023 Jul; 23(1):702. PubMed ID: 37495949
[TBL] [Abstract][Full Text] [Related]
10. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial].
Yang WY; Liu TF; Chen XJ; Guo Y; Li T; Qi BQ; Liu F; Chang LX; Ruan M; Liu XM; Zhang L; Zou Y; Chen YM; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Nov; 22(11):1172-1177. PubMed ID: 33172550
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia.
Qin Y; Han X; Wang L; Du P; Yao J; Wu D; Song Y; Zhang S; Tang L; Shi Y
Chin J Cancer Res; 2017 Oct; 29(5):402-410. PubMed ID: 29142459
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer.
Li W; Dong M; Huang S; Shi L; Yang H; Zhang Y; Gong J; Shi M; Wei L; Zhao L
Biomol Biomed; 2023 Mar; 23(2):310-316. PubMed ID: 36300280
[TBL] [Abstract][Full Text] [Related]
14. Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study.
Tian W; Wang Y; Zhou Y; Yao Y; Deng Y
Front Oncol; 2022; 12():777602. PubMed ID: 35547875
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
Wang C; Zhu S; Miao C; Wang Y; Chen J; Yuan S; Hu X
BMC Cancer; 2022 May; 22(1):542. PubMed ID: 35562713
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
Huang X; Li S; Shi W; Wang Y; Wan X; He J; Xu Y; Zhang W; Shi X; Chen R; Xu L; Zha X; Wang J
Br J Clin Pharmacol; 2023 Jan; 89(1):372-379. PubMed ID: 36001055
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study on the efficacy and safety between pegfilgrastim (PEG-rhG-CSF) and recombinant human granulocyte colony-stimulating factor in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation after hematological malignancy].
Yang F; Sun XD; Yuan L; Zhang JC; Hu JW; Liu N; Lou X; Su YF; Yu ZY; Chen JL; Li YH; Hu LD; Chen H; Jiang M
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):831-836. PubMed ID: 29166733
[No Abstract] [Full Text] [Related]
19. [A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer].
Jiang ZF; Xu FR; Fan J; Li BJ; Gao JN; Hu JW; Wang XJ; Zhang YQ; Wang JH; Li F; Liu Q; Liu YH; Wang S; Wang YS; Ouyang QC; Hu B; Sun GP; Zhang Y; Zang AM; Fan PZ; Wu CP; Liu J; Zhang HW; Wang W; Hu XC; Tang LL; Zhang J; Bao YY; Geng CZ; Sun Q; Zhang F; Yin YM; Jiang HC; An YH
Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1231-1235. PubMed ID: 29747310
[No Abstract] [Full Text] [Related]
20. [Effect and safety of pegylated recombinant human G-CSF on hematopoietic reconstitution after autologous hematopoietic stem cell transplantation in lymphoma patients].
Shen YG; Ji MM; Zheng Z; Tang W; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):940-945. PubMed ID: 36709186
[No Abstract] [Full Text] [Related]
[Next] [New Search]